BioSpace News Archive

Marinus Pharmaceuticals , Inc. today announced it has received $30 million in funding under the existing Oaktree Capital Management, L.P. (Oaktree) credit agreement.

Acer Therapeutics Inc. today announced that it has received notice from The Nasdaq Stock Market (Nasdaq) on March 30, 2022 informing Acer that it has regained compliance with the minimum market value of listed securities standard under Nasdaq List Standard.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of a post-hoc analysis from the N-MOmentum Phase 3 pivotal trial of UPLIZNA, showing that the medicine was safe and effective in NMOSD patients who were treated with UPLIZNA after having only one attack.

The Alliance for Regenerative Medicine, the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, today released its 2021 Annual Report, showcasing a year of significant advances and forecasting continued growth ahead.

SK Life Science, Inc. will present data from a pooled analysis from studies C013/C017 OLEs and C021 evaluating the cognitive and psychiatric treatment-related adverse events during adjunctive treatment with anti-seizure medication XCOPRI® CV at the American Academy of Neurology Annual Meeting, held in-person in Seattle April 2–7, 2022.

Royal Philips announced the launch of Ultrasound Workspace[OLK1] at the American College of Cardiology’s Annual Scientific Session & Expo. Philips Ultrasound Workspace [1] is an industry leading vendor-neutral echocardiography image analysis and reporting solution that can be accessed remotely via a browser.

Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize gene therapy with its commensal virome platform, announced a pre-print publication in bioRxiv on the first comprehensive examination in humans of anellovirus-specific antibody responses.

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2021.

Jasper Therapeutics, Inc. (NASDAQ: JSPR) today announced that updated data from the Company’s ongoing study of JSP191 as single agent conditioning prior to allogeneic hematopoietic stem cell (HSC) re-transplant in patients with severe combined immunodeficiency (SCID) has been accepted for presentation as a late-breaking poster at the 2022 Clinical Immunology Society (CIS) Annual Meeting.

Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biopharma company developing cellular therapies for aging-related illnesses, chronic disorders, and other specific life-threatening conditions, announced the publication of results from a Phase 1 trial testing Lomecel-B on patients with mild Alzheimer’s disease (AD) in Alzheimer’s & Dementia®: The Journal of the Alzheimer’s Association.